|
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck |
Travel, Accommodations, Expenses - EUSA Pharma; Janssen |
|
|
|
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Kite/Gilead; Novartis; Roche; Takeda |
Travel, Accommodations, Expenses - Janssen; Kite/Gilead; Takeda |
|
|
Honoraria - Pfizer; Roche |
Consulting or Advisory Role - Amgen; Kite/Gilead; Roche |
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Janssen; Kite, a Gilead company; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Janssen; Roche |
Consulting or Advisory Role - Celgene; Janssen; Roche |
Travel, Accommodations, Expenses - Celgene; Eisai; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Nordic Nanovector; Takeda |
Research Funding - Amgen; Roche; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |